rs,
change Plaza, Bandra-Kurla Complex, Bandra, Mumbai - 400 051. Symbol: HIKAL BSE Ltd., P J Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 524735 Dear Sir/Madam, Subject: Results Presentati
Rs. 380
lity to global supply chains and procurement cycles. For Q1 FY26, our consolidated revenue stood at Rs. 380 Cr, with EBITDA at Rs. 25 Cr, reflecting a lower-than-forecasted start to the financial year. Our
Rs. 25
and procurement cycles. For Q1 FY26, our consolidated revenue stood at Rs. 380 Cr, with EBITDA at Rs. 25 Cr, reflecting a lower-than-forecasted start to the financial year. Our pharmaceutical segment del
Rs. 203
ower-than-forecasted start to the financial year. Our pharmaceutical segment delivered revenue of Rs. 203 Cr, with an EBIT margin of -12.9%. After the US FDA audit conducted in February 2025, we received a
12.9%
nancial year. Our pharmaceutical segment delivered revenue of Rs. 203 Cr, with an EBIT margin of -12.9%. After the US FDA audit conducted in February 2025, we received an Official Action Indicated (OAI)
Rs. 178
r future growth in Japan and key LATAM markets. Our crop protection business reported revenue of Rs. 178 Cr with an EBIT margin of 9.7%. The business remained largely flat on a YoY basis, reflecting persi
9.7%
LATAM markets. Our crop protection business reported revenue of Rs. 178 Cr with an EBIT margin of 9.7%. The business remained largely flat on a YoY basis, reflecting persistent global overcapacity, and
22.4%
MARY COMMENTARY Rs. In Crs Revenue EBITDA EBITDA% PAT EPS Q4FY25 Q1FY25 Q1FY26 552 124 22.4% 50 4.08 407 58 14.3% 5 0.42 380 25 6.5% (23) (1.84) CONSOLIDATED: REVENUE SPLIT% Rs.
14.3%
rs Revenue EBITDA EBITDA% PAT EPS Q4FY25 Q1FY25 Q1FY26 552 124 22.4% 50 4.08 407 58 14.3% 5 0.42 380 25 6.5% (23) (1.84) CONSOLIDATED: REVENUE SPLIT% Rs. In Crs Q4FY25 Q1FY25 Q1
6.5%
DA% PAT EPS Q4FY25 Q1FY25 Q1FY26 552 124 22.4% 50 4.08 407 58 14.3% 5 0.42 380 25 6.5% (23) (1.84) CONSOLIDATED: REVENUE SPLIT% Rs. In Crs Q4FY25 Q1FY25 Q1FY26 Pharmaceuticals C
64%
CONSOLIDATED: REVENUE SPLIT% Rs. In Crs Q4FY25 Q1FY25 Q1FY26 Pharmaceuticals Crop-Protection 64% 36% 56% 44% 53% 47% Revenue recorded at Rs 380 Crore; impacted by deferred offtake post USFD
36%
LIDATED: REVENUE SPLIT% Rs. In Crs Q4FY25 Q1FY25 Q1FY26 Pharmaceuticals Crop-Protection 64% 36% 56% 44% 53% 47% Revenue recorded at Rs 380 Crore; impacted by deferred offtake post USFDA OAI